Therapy News and Research

RSS

Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting

Celldex Therapeutics, Inc., today announced the presentation of complete data for the primary endpoint of ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed glioblastoma multiforme (GBM).

21 Nov 2010

Scientologists target Aborigines with “drug bombs”

The Northern Territory (NT) Health Department of Australia last Saturday warned the Church of Scientology that its drug detoxification therapy, being promoted to Aborigines in Australia by the church was dangerous for people with kidney problems.

21 Nov 2010

Dr. Gupta interviewed for upcoming segment of World Progress Report

Dr. Sameer Gupta, of Vein Clinic PA, was recently interviewed for an upcoming segment of World Progress Report, hosted by Joan Lunden.

20 Nov 2010

Gore joins vascular, endovascular leaders to honor physicians receiving annual recognition

W. L. Gore & Associates joined with leaders from across the vascular and endovascular community to honor a distinguished group of eight physicians receiving the 2010 Pioneers in Performance Awards.

20 Nov 2010

Simple strategies to cope with holiday stress

Dr. Richard Blonna, author, life coach, and stress management expert, offers five simple strategies for managing holiday stress. His approach to managing the worry and anxiety associated with holiday stress is adapted from his new book, Stress Less, Live More; How Acceptance and Commitment Therapy Can Help You Live a Busy Yet Balanced Life.

20 Nov 2010

BizVotes.com identifies Dr. Ryan Groelz as Best Chiropractor in Broomfield, Colorado

Dr. Ryan Groelz of Rock Creek Spine and Rehabilitation Center has been voted the 'Best Chiropractor in Broomfield, Colorado' by BizVotes.com. A popular consumer website, BizVotes.com helps communities identify the best local businesses through an online voting system. Rock Creek Spine and Rehabilitation Center is currently listed in the top choice for chiropractic care in Broomfield.

20 Nov 2010

Palmetto GBA to cover PTNS therapy for patients with overactive bladder

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that Palmetto GBA for California, Nevada and Hawaii, a regional Medicare carrier, now covers posterior tibial nerve stimulation using the Urgent PC Neuromodulation System for the treatment of the symptoms of overactive bladder.

20 Nov 2010

New international guidelines launched to protect health workers against HIV, TB

Health workers are at the frontline in providing prevention, treatment and care for people living with HIV and TB throughout the world. They are at risk of occupational exposure to HIV and TB but often themselves lack adequate access to protection and treatment. To address this gap, new international guidelines are being launched today by the International Labour Organization, WHO and the Joint United Nations Programme on HIV/AIDS.

20 Nov 2010

Scientists discover Notch pathway may play a role in alcohol's protective effects

Many studies support the assertion that moderate drinking is beneficial when it comes to cardiovascular health, and for the first time scientists have discovered that a well-known molecule, called Notch, may be behind alcohol's protective effects. Down the road, this finding could help scientists create a new treatment for heart disease that mimics the beneficial influence of modest alcohol consumption.

20 Nov 2010

Myrexis announces poster presentation on Azixa at Neuro-Oncology Scientific Meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced a poster presentation of its lead product candidate Azixa (verubulin, MPC-6827) at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day in Montreal, Canada.

20 Nov 2010

Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that the Company will present new data at the American Society of Nephrology meeting being held in Denver, Colorado, on its late-stage investigational drug Soluble Ferric Pyrophosphate, which is being studied for the treatment of iron-deficiency anemia in ESRD patients.

20 Nov 2010

One-third of malaria-endemic countries are complying with WHO malaria drug efficacy monitoring standards, report says

Thirty-four percent of malaria-endemic countries are complying with WHO guidelines to monitor artemisinin resistance within their borders, the agency said in a report on Thursday, CBS News reports (11/18). Reuters reports that artemisinin "is the best drug available against malaria, especially when used in artemisinin combination therapy (ACT), which combines it with other drugs that finish off the [malaria] parasite" (Nebehay, 11/18).

20 Nov 2010

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.

20 Nov 2010

Platelet Rich Plasma Therapy reduces pain and improves function in knee osteoarthritis patients

The first American study that positions Platelet Rich Plasma Therapy (PRP) as a viable means in managing knee osteoarthritis, appeared today in the December issue of the American Journal of Physical Medicine & Rehabilitation (AJPMR). The study, authored by Dr. Steven Sampson of the Orthohealing Center in Los Angeles, details the account of 14 patients with primary and secondary knee osteoarthritis receiving three platelet-rich plasma injections in the affected knee at 4-week intervals with one year follow up.

20 Nov 2010

Siemens to unveil Biograph mMR system at RSNA Annual Meeting

At the 96th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), November 28 - December 2 in Chicago, Siemens Healthcare (Booth #822, East Building/Lakeside Center, Hall D) will unveil the Biograph mMR, the world's first integrated whole-body molecular Magnetic Resonance (MR) system with simultaneous data acquisition technology, currently undergoing clinical use testing.

20 Nov 2010

NEXTERONE Premixed Injection uses CyDex Captisol technology platform

CyDex Pharmaceuticals, Inc. today announced that Prism Pharmaceuticals' NEXTERONE (amiodarone HCL) Premixed Injection, which recently received supplemental new drug application (sNDA) approval from the U.S. Food and Drug Administration, makes use of the patent-protected CyDex Captisol technology platform.

20 Nov 2010

NJISA experts to discuss science, impact and current state of Alzheimer's disease in America

The New Jersey Institute for Successful Aging (NJISA) at the UMDNJ-School of Osteopathic Medicine, one of the country's leading providers of geriatric care, research and education, is making experts available who can discuss the science, impact and current state of Alzheimer's disease in America.

20 Nov 2010

Xanodyne Pharmaceuticals decides to voluntarily remove propoxyphene from the U.S. market

Xanodyne Pharmaceuticals Inc. which makes Darvon and Darvocet, the brand version of the prescription pain medication propoxyphene, has agreed to withdraw the medication from the U.S. market at the request of the U.S. Food and Drug Administration. The FDA has also informed the generic manufacturers of propoxyphene-containing products of Xanodyne's decision and requested that they voluntarily remove their products as well.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

TTF therapy may increase median survival time in patients with recurrent glioblastoma tumors

Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy.

20 Nov 2010

Therapy News and Research

Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting

Scientologists target Aborigines with “drug bombs”

Dr. Gupta interviewed for upcoming segment of World Progress Report

Gore joins vascular, endovascular leaders to honor physicians receiving annual recognition

Simple strategies to cope with holiday stress

BizVotes.com identifies Dr. Ryan Groelz as Best Chiropractor in Broomfield, Colorado

Palmetto GBA to cover PTNS therapy for patients with overactive bladder

New international guidelines launched to protect health workers against HIV, TB

Scientists discover Notch pathway may play a role in alcohol's protective effects

Myrexis announces poster presentation on Azixa at Neuro-Oncology Scientific Meeting

Data from Rockwell Medical's Phase IIb study of SFP presented at ASN meeting

One-third of malaria-endemic countries are complying with WHO malaria drug efficacy monitoring standards, report says

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Platelet Rich Plasma Therapy reduces pain and improves function in knee osteoarthritis patients

Siemens to unveil Biograph mMR system at RSNA Annual Meeting

NEXTERONE Premixed Injection uses CyDex Captisol technology platform

NJISA experts to discuss science, impact and current state of Alzheimer's disease in America

Xanodyne Pharmaceuticals decides to voluntarily remove propoxyphene from the U.S. market

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

TTF therapy may increase median survival time in patients with recurrent glioblastoma tumors

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News